Lombard Medical product receives US approval for commercial sale

Lombard Medical, the AIM-listed medical technology firm focused on innovative vascular products, has announced that its Aorfix product has been approved for commercial sale in the US.

Lombard Medical, the AIM-listed medical technology firm focused on innovative vascular products, has announced that its Aorfix product has been approved for commercial sale in the US.

Aorfix, the company's flexible stent graft for the endovascular repair of abdominal aortic aneurysms (AAAs) was found by the US Food and Drug Administration (FDA) to treat a larger patient population than competing devices.

Lombard said: "Independent market research suggests that the U.S. market for the repair of AAAs is worth over $600m per annum, is forecast to grow at approximately 8.0% per annum."

The approval triggers receipt of the £14.1m second tranche of the two-tranche placing and subscription for funds, which will be used to launch Aorfix in the US. It also triggers the company's ability to draw down $2.5m from the $5.0m loan facility granted by its exclusive distribution partner in Japan, Medico's Hirata Inc.

"FDA approval of Aorfix is a major milestone for the company and sets the stage for the next chapter in the company's growth," said Lombard's Chief Executive Simon Hubbert.

"I would like to thank all of our employees, investigators and clinical advisors for their support and hard work, without which development and approval of Aorfix would not have been possible."

"We look forward to launching Aorfix in the U.S. through our own sales force and are confident of securing a meaningful share of this growing market."

Recommended

Imperial Brands has an 8.3% yield – but what’s the catch?
Share tips

Imperial Brands has an 8.3% yield – but what’s the catch?

Tobacco company Imperial Brands boasts an impressive dividend yield, and the shares look cheap. But investors should beware, says Rupert Hargreaves. H…
20 May 2022
Investing in drugmakers: uncommon profits from curing rare diseases
Share tips

Investing in drugmakers: uncommon profits from curing rare diseases

Treatments for medical conditions with only a small number of sufferers can still be very attractive for pharmaceutical companies and investors becaus…
20 May 2022
Share tips of the week – 20 May
Share tips

Share tips of the week – 20 May

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
20 May 2022
Delivering profits: should you buy Royal Mail shares?
Share tips

Delivering profits: should you buy Royal Mail shares?

The volume of parcels delivered by Royal Mail soared during the pandemic, and so did its profits. But it has been coming under pressure lately. So, as…
19 May 2022

Most Popular

The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves looks at the FTSE 100’s top yielding stocks for income investors to consider.
18 May 2022
Imperial Brands has an 8.3% yield – but what’s the catch?
Share tips

Imperial Brands has an 8.3% yield – but what’s the catch?

Tobacco company Imperial Brands boasts an impressive dividend yield, and the shares look cheap. But investors should beware, says Rupert Hargreaves. H…
20 May 2022
Barry Norris: we’re already in the 1970s. Here’s how to invest
Investment strategy

Barry Norris: we’re already in the 1970s. Here’s how to invest

Merryn talks to Barry Norris of Argonaut capital about the parallels between now and the 1970s; the transition to “green” energy; and the one sector w…
19 May 2022